The Association of Serum Insulin-like Growth Factor-I with Mortality, Cardiovascular Disease, and Cancer in the Elderly: a Population-based Study
Overview
Authors
Affiliations
Context: Numerous studies have investigated the effect of serum IGF-I concentration on aging and different aging-related diseases, e.g. cardiovascular disease (CVD) and cancer. Decreased as well as increased levels have been reported to be associated with reduced life expectancy in humans.
Objective: This study investigates the association of serum IGF-I concentration with all-cause and cause-specific mortality of community-dwelling older persons and the development of CVD and cancer.
Design, Setting, And Participants: Data were used from the Longitudinal Aging Study Amsterdam (LASA), an ongoing multidisciplinary cohort study in the general Dutch population of older persons (≥65 yr old) where serum IGF-I was measured (n = 1273). The mortality information was ascertained using the International Classification of Diseases, 10th revision, and the presence or absence of CVD and cancer by self-reports with a follow-up of 11.6 yr.
Main Outcome Measure: We measured all-cause, CVD, and cancer mortality and nonfatal CVD and cancer.
Results: Fully adjusted Cox proportional hazards models demonstrated an increased risk of all-cause mortality for older persons with IGF-I values in the lowest quintile as compared to the middle quintile [hazard ratio (HR), 1.28; 95% confidence interval (CI), 1.01-1.63]. A more than 2-fold increased risk of CVD mortality was revealed for both low-normal (HR, 2.39; 95% CI, 1.22-4.66) and high-normal (HR, 2.03; 95% CI, 1.02-4.06) IGF-I values. Significant associations of serum IGF-I with nonfatal CVD and fatal and nonfatal cancer were not observed.
Conclusions: Results suggest a U-shaped relationship between IGF-I level and mortality, with fatal CVD as the most critical outcome in community-dwelling older persons.
Li T, Zhao Y, Yang X, Feng Y, Li Y, Wu Y J Endocrinol Invest. 2022; 45(12):2221-2231.
PMID: 35596917 DOI: 10.1007/s40618-022-01819-1.
Safety of Pediatric rhGH Therapy: An Overview and the Need for Long-Term Surveillance.
Cianfarani S Front Endocrinol (Lausanne). 2022; 12:811846.
PMID: 35002983 PMC: 8740026. DOI: 10.3389/fendo.2021.811846.
PCOS and Depression: Common Links and Potential Targets.
Kolhe J, Chhipa A, Butani S, Chavda V, Patel S Reprod Sci. 2021; 29(11):3106-3123.
PMID: 34642910 DOI: 10.1007/s43032-021-00765-2.
GH Replacement in the Elderly: Is It Worth It?.
Ricci Bitti S, Franco M, Albertelli M, Gatto F, Vera L, Ferone D Front Endocrinol (Lausanne). 2021; 12:680579.
PMID: 34211437 PMC: 8239420. DOI: 10.3389/fendo.2021.680579.
Castro-Diehl C, Ehrbar R, Obas V, Oh A, Vasan R, Xanthakis V PLoS One. 2021; 16(5):e0251308.
PMID: 33989340 PMC: 8121535. DOI: 10.1371/journal.pone.0251308.